Press release
Pancreatic Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)
Key Takeaways from the Pancreatic Cancer Pipeline Report
* DelveInsight's Pancreatic Cancer pipeline report depicts a robust space with 290+ active players working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.
* The leading Pancreatic Cancer Companies working in the market include ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
* Promising Pancreatic Cancer Pipeline Therapies in the various stages of development include Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.
* April 2024- Amgen- A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion. The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
* April 2024:- AstraZeneca- LYNPARZA Tablets 100 mg, 150mg General Drug Use-results Study in Patients on Maintenance Treatment After Platinum-based Chemotherapy for BRCA Mutated Curatively Unresectable Pancreas Cancer. To collect and characterise the incidence of adverse events related to the safety specifications of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic cancer under the actual post-marketing use of LYNPAZA.
* April 2024:- EBG MedAustron GmbH- Phase II Trial of Hypo-fractionated Highly Conformal Radiotherapy for Locally Advanced Pancreatic Carcinomas. This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.
* April 2024:- Radboud University Medical Center- Intratumoral Holmium Microspheres Brachytherapy for Patients with Pancreatic Cancer; a Single Center, Non-randomized, Feasibility Study in an Open Surgical Setting - the SLOTH1 Study. This is a feasibility study in which patients with pancreatic cancer are treated with intratumoral holmium microsphere injections.
Request a sample and discover the recent advances in Pancreatic Cancer Treatment Drugs @ Pancreatic Cancer Pipeline Report [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
In the Pancreatic Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Pancreatic Cancer Overview
Pancreatic cancer is a disease in which malignant or cancer cells form in the tissues of the pancreas. Pancreatic cancer begins in the tissues of the pancreas - an organ in the abdomen that lies behind the lower part of the stomach. Pancreatic cancer most frequently arises from pancreatic intraepithelial neoplasia (PanIN), the classic pre-neoplastic lesions, but can also arise from larger precursor lesions, namely, intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms.
Find out more about Pancreatic Cancer Therapeutics Assessment @ Pancreatic Cancer Preclinical and Discovery Stage Products [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pancreatic Cancer Emerging Drugs Profile
Pamrevlumab: FibroGen
Devimistat: Cornerstone Pharmaceuticals
Masitinib: AB Science
SBP-101: Panbela Therapeutics
TAS-102: Taiho Pharmaceutical Co., Ltd.
RAIN-32: Rain Oncology
IMX-110: Immix Biopharma
Pancreatic Cancer Pipeline Therapeutics Assessment
There are approx. 290+ key companies which are developing the therapies for Pancreatic Cancer. The companies which have their Pancreatic Cancer drug candidates in the most advanced stage, i.e. phase III include, FibroGen.
DelveInsight's Pancreatic Cancer Pipeline Report covers around 300+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Pancreatic Cancer Pipeline Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Learn more about the emerging Pancreatic Cancer Pipeline Therapies @ Pancreatic Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Pancreatic Cancer Pipeline Report
* Coverage- Global
* Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Pancreatic Cancer Companies- ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
* Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.
Dive deep into rich insights for new drugs for Pancreatic Cancer Treatment, Visit @ Pancreatic Cancer Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Pancreatic Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Pancreatic Cancer - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Pamrevlumab: FibroGen
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Niraparib: Innovent Biologics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* CT041: CARsgen Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* ONC 212: Oncoceutics
* Drug profiles in the detailed report.....
* Inactive Products
* Pancreatic Cancer Key Companies
* Pancreatic Cancer Key Products
* Pancreatic Cancer- Unmet Needs
* Pancreatic Cancer- Market Drivers and Barriers
* Pancreatic Cancer- Future Perspectives and Conclusion
* Pancreatic Cancer Analyst Views
* Pancreatic Cancer Key Companies
* Appendix
For further information on the Pancreatic Cancer Pipeline therapeutics, reach out to Pancreatic Cancer Unmet Needs and Analyst Views [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Pamrevlumab: FibroGen
Devimistat: Cornerstone Pharmaceuticals
Masitinib: AB Science
SBP-101: Panbela Therapeutics
TAS-102: Taiho Pharmaceutical Co., Ltd.
RAIN-32: Rain Oncology
IMX-110: Immix Biopharma
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pancreatic-cancer-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) here
News-ID: 3487983 • Views: …
More Releases from ABNewswire
Doctor Roya Redefines Luxury - Beyond Materialism: The Emotional Weight of Thing …
Dr. Roya Jafari-Hassad Advocates her Philosophy - Feeling Your Best is the Ultimate Status Symbol
New York, USA - May 19, 2024 - In today's world, luxury is often associated with expensive brands and the latest trends. A coveted designer bag or a high-end watch might seem like the ultimate status symbol, but Dr. Roya Jafari-Hassad, a leading expert in the State of New York, believes it's time to redefine what…
Revolutionizing On-the-Go Jam Sessions: Anygig Guitar Unveils Innovative Designs
In the bustling world of music, where creativity knows no bounds, musicians are constantly seeking instruments that match their nomadic lifestyle without compromising on quality. Enter Anygig Guitar, a trailblazing brand dedicated to crafting travel-friendly instruments that redefine the boundaries of portable music-making. With a diverse lineup featuring headless guitars [https://www.anygigguitar.com/], full-scale models, and everything in between, Anygig Guitar has emerged as the go-to choice for musicians on the move.
"At…
Schneider Electric appoints Ruben Llanes as CEO of Digital Grid
Schneider Electric, the leader in the digital transformation of energy management and automation, has appointed Ruben Llanes as Chief Executive Officer of Digital Grid. Digital Grid aims to accelerate grid modernization, from grid to prosumer, under the pillars of innovation, adoption and partnerships.
Previously CEO of AutoGrid, Llanes delivered growth, introduced improved processes and methods, and launched new solutions, including turnkey VPPs. His tenure culminated with the sale of AutoGrid to…
Celebrating Victory: "The Voice of Lithuania. Generations" 2nd Season Won by Boy …
Image: https://www.abnewswire.com/uploads/9756fdbda22425795f03c6a1d7cd9039.jpg
This past Sunday marked the grand finale of "Lithuania's Voice. Generations" at the Kaunas "Zalgiris" Arena, a momentous event that showcased the pinnacle of talent and competition. Nine finalists vied for the coveted 15,000 cash prize and the contract with ELITAZ Music [https://elitaz.lt/], each delivering breathtaking musical and visual performances crafted in collaboration with the project team specifically for this climactic evening.
Prior to the final showdown, esteemed guests gathered…
More Releases for Pancreatic
Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Panc …
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of…
Pancreatic Cancer Treatment
Pancreatic Cancer Treatment Market describes its growth, size, share, Forecast and trends to 2025
Pancreatic Cancer Treatment Market Production and Demand Analysis 2019 to 2025
Pancreatic Cancer Treatment Market 2019 Manufacturing Analysis and Development Forecast 2025
Pancreatic Cancer Treatment Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025
Pancreatic Market to Insight By 2025: Top Key Vendors
Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to…
Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease.
Download the sample report at: https://www.pharmaproff.com/request-sample/1024
Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI…
Pancreatic Cancer Pipeline Review H1 2019
Pancreatic Cancer - Pipeline Review, H1 2017
Summary
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.
Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and…
Pancreatic Cancer Drug Pipeline Analysis
“Pancreatic Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Pancreatic Cancer. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each…
Exocrine Pancreatic Insufficiency Market 2013
Transparency Market Research has published a new market report titled, “Exocrine Pancreatic Insufficiency Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 – 2023.” According to the report, the exocrine pancreatic insufficiency market is anticipated to expand at a CAGR of 8.3% from 2015 to 2023 to reach US$2.85 Bn by 2023.
Browse the full Exocrine Pancreatic Insufficiency Market – (Therapeutic – Pancreatic Enzyme Replacement Therapy (Creon, Zenpep,…
